# CNTF Gene: Structure, Function, and Clinical Significance ## Key Takeaways - Ciliary neurotrophic factor (CNTF) is a cytosolic cytokine, not secreted via the ER-Golgi pathway, released upon cellular injury to promote neuronal and glial survival. It signals through a tripartite receptor complex (CNTFRα, gp130, LIFRβ) activating JAK/STAT, MAPK/ERK, and PI3K/AKT pathways. - The human CNTF gene is located on chromosome 11q12.1 and comprises two exons; its promoter contains binding sites for transcription factors like STAT3 and NF-κB, and is regulated by epigenetic modifications and tissue-specific enhancers. - CNTF's mature protein is a stable, four-helix bundle cytokine lacking a signal peptide, with distinct receptor-binding epitopes on helices A, C, and D that interact with CNTFRα, gp130, and LIFRβ, respectively. - Pathogenic variants include a common splice site mutation (c.397G>A) that acts as a modifier for earlier onset and faster progression of amyotrophic lateral sclerosis (ALS) in homozygous carriers. - Therapeutic applications of recombinant CNTF and its analogs have been explored for obesity, ALS, and retinal degeneration, with challenges including immunogenicity and bioavailability, leading to alternative delivery methods like encapsulated cell-based systems and gene therapy. - CNTF plays a role in host-pathogen interactions, with viruses like HTLV-1 mimicking its downstream STAT3 activation for T-cell survival, and *M. tuberculosis* modulating CNTF expression to evade immune responses. --- ## Executive Summary & Key Metadata Ciliary neurotrophic factor (CNTF) is a polypeptide cytokine belonging to the interleukin-6 (IL-6) family of neuropoietic cytokines. Unlike classical growth factors, CNTF is a cytosolic protein that is not secreted via the canonical endoplasmic reticulum–Golgi pathway; it is released upon cellular injury, functioning as a lesion-associated survival factor for neurons and glia. The gene encoding CNTF is located on human chromosome 11q12.1 and is highly conserved across vertebrates. The mature protein adopts a four-helix bundle topology characteristic of the IL-6 family, and it signals through a tripartite receptor complex comprising CNTFRα, gp130 (IL6ST), and LIFRβ (leukemia inhibitory factor receptor beta). This engagement triggers the JAK/STAT, MAPK/ERK, and PI3K/AKT cascades, with profound implications for neuronal survival, oligodendrocyte differentiation, and metabolic regulation. The clinical significance of CNTF extends from rare null mutations associated with neurodegenerative phenotypes to its repurposing as a therapeutic agent for obesity, retinal degeneration, and motor neuron disease. The gene product has also been implicated in cancer biology, where its receptor CNTFRα is aberrantly expressed in several solid tumors. This reference manual provides an exhaustive, biophysically grounded analysis of the CNTF gene, its protein architecture, signaling networks, pathogenic variants, and therapeutic targeting. | **Metadata Field** | **Value** | | --- | --- | | HGNC Symbol | CNTF | | UniProt Accession | P26441 | | Representative PDB ID | 1CNT (murine), 3Q48 (human CNTF/CNTFRα complex) | | Chromosomal Locus | 11q12.1 (GRCh38: chr11:58,622,665–58,625,664) | | Primary Molecular Function | Cytokine activity; neurotrophin; ligand for CNTFRα/gp130/LIFRβ receptor complex | | Disease & Pathology Associations | Amyotrophic lateral sclerosis (modifier), obesity, multiple sclerosis, retinal degeneration, cancer (CNTFRα overexpression) | | Expression Pattern | CNS neurons, Schwann cells, skeletal muscle, adipose tissue (low basal; injury-induced) | | Post-Translational Modifications | N-linked glycosylation (not required for activity); no signal peptide; intracellular retention | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Gene Coordinates and Structural Organization The human CNTF gene (NCBI Gene ID: 1270) spans approximately 3.0 kilobases of genomic DNA on the long arm of chromosome 11 at cytogenetic band q12.1. The precise GRCh38/hg38 coordinates are chr11:58,622,665–58,625,664 (minus strand). The gene is composed of two exons separated by a single intron of approximately 1.2 kb. Exon 1 (approximately 200 bp) contains the 5' untranslated region (UTR) and the coding sequence for the first 39 amino acids, including the initiator methionine. Exon 2 (approximately 600 bp) encodes the remaining 161 amino acids and the 3' UTR, which contains multiple AU-rich elements (AREs) that confer mRNA instability. The promoter region of CNTF lacks a canonical TATA box but contains a GC-rich region with multiple Sp1 binding sites. A CCAAT box is present at approximately −80 bp relative to the transcription start site (TSS). The promoter also harbors binding sites for the transcription factors NF-κB, AP-1, and STAT3, which are consistent with the gene's inducibility by inflammatory cytokines and cellular stress. Notably, the CNTF promoter is methylated in non-neuronal tissues, contributing to its restricted expression pattern. ### 1.2 Enhancer Elements and Chromatin Architecture Chromatin immunoprecipitation sequencing (ChIP-seq) data from the ENCODE project reveal that the CNTF locus is embedded within a topologically associating domain (TAD) that includes the neighboring genes *KIAA0652* and *TBC1D4*. A putative enhancer element located approximately 15 kb upstream of the TSS (chr11:58,607,000–58,608,500) shows H3K27ac marks in neural progenitor cells and adult brain tissue. This enhancer is bound by the neurogenic transcription factors NeuroD1 and ASCL1, providing a mechanistic basis for the neuron-specific expression of CNTF. In skeletal muscle, a distinct enhancer at chr11:58,630,000–58,631,500 is bound by MyoD and MEF2, explaining the low-level expression of CNTF in myocytes. ### 1.3 Alternative Splicing and Isoforms The CNTF gene undergoes minimal alternative splicing. The predominant transcript (NM_000614.4) encodes the full-length 200-amino-acid precursor protein. A minor splice variant lacking exon 1 (NR_033410.1) has been annotated as a non-coding RNA, but its functional relevance remains unclear. No secreted isoforms arising from alternative splicing have been identified; the absence of a signal peptide in all known isoforms reinforces the cytosolic localization of CNTF. ### 1.4 Pseudogenes and Homologs A processed pseudogene of CNTF has been identified on chromosome 2 (CNTFP1), but it is transcriptionally silent. Orthologs of CNTF are present in all vertebrates examined, including zebrafish, *Xenopus*, and mammals. The murine Cntf gene (chromosome 19) shares 82% amino acid identity with the human protein. Interestingly, the CNTF gene is absent from the genomes of birds and reptiles, suggesting a lineage-specific loss that correlates with the evolution of the avian visual system. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Sequence and Domain Boundaries The human CNTF precursor is 200 amino acids long (UniProt P26441). The mature protein, which is not proteolytically processed, spans residues 1–200. The protein lacks a signal peptide and a transmembrane domain, confirming its cytosolic localization. The primary sequence can be divided into four α-helical regions (helices A–D) connected by three loop regions (AB, BC, CD), a topology shared by all long-chain four-helix bundle cytokines. - **Helix A**: residues 14–44 - **AB loop**: residues 45–62 - **Helix B**: residues 63–96 - **BC loop**: residues 97–110 - **Helix C**: residues 111–145 - **CD loop**: residues 146–155 - **Helix D**: residues 156–190 - **C-terminal tail**: residues 191–200 ### 2.2 Quaternary Structure and Receptor Binding Epitopes The CNTF monomer adopts an up-up-down-down four-helix bundle with a left-handed twist. The bundle is stabilized by extensive hydrophobic interactions along the helix interfaces. The protein contains two disulfide bonds (Cys17–Cys94 and Cys45–Cys111) that are not required for folding but contribute to thermal stability. The receptor-binding epitopes of CNTF have been mapped by alanine-scanning mutagenesis and co-crystallization studies. Three distinct binding sites are recognized: 1. **Site I** (helices A and C, residues 23–35 and 118–130): binds to the CNTFRα subunit with nanomolar affinity (Kd ≈ 0.5 nM). This interaction is the primary determinant of cell-type specificity. 2. **Site II** (helix A and the AB loop, residues 14–25 and 50–60): binds to gp130 (IL6ST). This interaction is required for signal transduction. 3. **Site III** (helix D, residues 160–180): binds to LIFRβ. The Site III epitope is conserved among IL-6 family cytokines and is essential for the formation of the hexameric signaling complex. ### 2.3 Structural Comparison with IL-6 Family Members CNTF shares 25–30% sequence identity with IL-6, LIF, and oncostatin M (OSM). Despite low sequence identity, the three-dimensional structures are superimposable with a root-mean-square deviation (RMSD) of approximately 1.5 Å over the core helix bundle. The primary structural distinction is the length of the AB loop, which is shorter in CNTF than in IL-6, and the absence of a glycosylation site in the CD loop. These differences account for the unique receptor specificity of CNTF. ### 2.4 Post-Translational Modifications and Stability CNTF is not glycosylated in its native form, and the recombinant protein produced in *E. coli* is fully functional, which has facilitated structural and biophysical studies. The protein is highly stable, with a melting temperature (Tm) of approximately 65°C as determined by circular dichroism spectroscopy. The stability is attributed to the extensive hydrophobic core and the two disulfide bonds. > **[Interactive 3D Protein Visualizer: Load CNTF (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P26441)** The interactive visualizer allows users to explore the four-helix bundle, rotate the structure, and highlight the receptor-binding epitopes (Site I, II, III). The tool also provides access to the experimentally determined structures of CNTF in complex with its receptors (PDB: 3Q48), enabling a detailed examination of the protein-protein interfaces. --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 The Tripartite Receptor Complex CNTF initiates signaling by binding sequentially to CNTFRα, gp130, and LIFRβ. CNTFRα is a glycosylphosphatidylinositol (GPI)-anchored protein that lacks an intracellular domain. The binding of CNTF to CNTFRα induces a conformational change that promotes the recruitment of gp130 and LIFRβ, forming a hexameric complex (2:2:2 stoichiometry). The assembly of this complex brings the cytoplasmic domains of gp130 and LIFRβ into close proximity, activating receptor-associated Janus kinases (JAK1, JAK2, and TYK2). ### 3.2 JAK/STAT Signaling Cascade The activated JAKs phosphorylate tyrosine residues on the cytoplasmic tails of gp130 and LIFRβ, creating docking sites for SH2-domain-containing proteins. The primary downstream effectors are the signal transducers and activators of transcription (STAT) proteins, particularly STAT3. Upon recruitment, STAT3 is phosphorylated at Tyr705, leading to its dimerization and nuclear translocation. In the nucleus, STAT3 dimers bind to gamma-activated sequences (GAS) in the promoters of target genes, including *SOCS3*, *BCL2*, *MCL1*, and *FOS*. The JAK/STAT pathway is negatively regulated by the suppressor of cytokine signaling (SOCS) family. SOCS3 is rapidly induced by CNTF signaling and binds to the phosphorylated tyrosine residues on gp130, targeting the receptor complex for proteasomal degradation. This feedback loop ensures that CNTF signaling is transient, with a duration of approximately 2–4 hours in cultured neurons. ### 3.3 MAPK/ERK and PI3K/AKT Pathways In addition to JAK/STAT, CNTF activates the mitogen-activated protein kinase (MAPK) pathway. The adaptor protein SHC binds to the phosphorylated gp130, leading to the activation of the GRB2/SOS/RAS complex and the subsequent phosphorylation of MEK1/2 and ERK1/2. ERK1/2 translocates to the nucleus and phosphorylates transcription factors such as ELK1 and CREB, promoting cell survival and differentiation. The PI3K/AKT pathway is activated through the recruitment of the p85 regulatory subunit of PI3K to the receptor complex. AKT phosphorylation at Ser473 and Thr308 inhibits pro-apoptotic proteins such as BAD and promotes the nuclear translocation of NF-κB, further enhancing cell survival. ### 3.4 Cellular Functions **Neuronal Survival:** CNTF is a potent survival factor for motor neurons, sensory neurons, and hippocampal neurons. In vitro, CNTF rescues motor neurons from trophic factor withdrawal-induced apoptosis with an EC50 of approximately 0.1 ng/mL. The survival effect is mediated primarily through the PI3K/AKT pathway, which maintains mitochondrial integrity and prevents cytochrome c release. **Oligodendrocyte Differentiation:** CNTF promotes the differentiation of oligodendrocyte precursor cells (OPCs) into mature oligodendrocytes. This effect is mediated by STAT3-dependent upregulation of myelin basic protein (MBP) and proteolipid protein (PLP). CNTF also enhances remyelination in animal models of demyelinating injury. **Metabolic Regulation:** CNTF acts on hypothalamic neurons to suppress appetite and increase energy expenditure. The anorexigenic effect is mediated by the activation of proopiomelanocortin (POMC) neurons and the inhibition of agouti-related peptide (AgRP) neurons. CNTF also promotes the browning of white adipose tissue, increasing thermogenesis. **Astrocyte Activation:** CNTF induces astrocyte proliferation and the upregulation of glial fibrillary acidic protein (GFAP), a hallmark of reactive gliosis. This effect is mediated by the JAK/STAT pathway and is observed in the injured CNS. ### 3.5 Protein-Protein Interaction Networks The CNTF interactome, as curated by BioGRID and STRING, includes the three receptor subunits (CNTFRα, gp130, LIFRβ), the JAK family kinases, and the STAT transcription factors. Additional interactors include the SH2-domain-containing phosphatase SHP2, which modulates the duration of MAPK signaling, and the adaptor protein SHC1. The interaction network is highly interconnected, with gp130 serving as a central hub that also mediates signaling by IL-6, IL-11, and OSM. ```mermaid sequenceDiagram participant CNTF participant CNTFRα participant gp130 participant LIFRβ participant JAK participant STAT3 participant SOCS3 CNTF->>CNTFRα: High-affinity binding (Site I) CNTFRα->>gp130: Recruitment (Site II) gp130->>LIFRβ: Heterodimerization (Site III) LIFRβ->>JAK: Activation (trans-phosphorylation) JAK->>gp130: Phosphorylates tyrosine residues gp130->>STAT3: Recruitment via SH2 domain STAT3->>STAT3: Phosphorylation at Tyr705 STAT3->>Nucleus: Dimerization and translocation Nucleus->>SOCS3: Transcriptional activation SOCS3->>gp130: Binds and promotes degradation SOCS3-->>JAK: Inhibition (negative feedback) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Null Mutations and Neurodegenerative Phenotypes The most well-characterized pathogenic variant in the CNTF gene is a G-to-A transition at the splice acceptor site of exon 2 (c.397G>A), which results in a frameshift and premature termination (p.Glu133ArgfsTer4). This variant is present in approximately 2–3% of the Caucasian population and leads to a complete absence of CNTF protein. Homozygous carriers of this null allele were initially reported to have no overt phenotype, suggesting functional redundancy with other neurotrophic factors. However, subsequent studies have demonstrated that CNTF null homozygotes exhibit an earlier onset of amyotrophic lateral sclerosis (ALS) symptoms and a more rapid disease progression. The variant is therefore classified as a disease modifier rather than a monogenic cause of neurodegeneration. ### 4.2 Missense Variants and Functional Consequences Several rare missense variants have been identified in the CNTF gene through exome sequencing: - **p.Arg28Gln (c.83G>A)**: Located in Helix A, within the Site I receptor-binding epitope. This variant reduces the binding affinity for CNTFRα by approximately 10-fold, as measured by surface plasmon resonance. It is associated with a mild reduction in motor neuron survival in vitro. - **p.Leu36Pro (c.107T>C)**: This substitution introduces a kink in Helix A, destabilizing the four-helix bundle. The variant protein is prone to aggregation and is retained in the cytoplasm, leading to a loss of function. - **p.Val170Met (c.508G>A)**: Located in Helix D, within the Site III epitope. This variant reduces the affinity for LIFRβ and impairs the activation of the JAK/STAT pathway. It has been identified in patients with late-onset retinal degeneration. ### 4.3 ClinVar Classifications and Disease Associations As of the latest ClinVar release, the CNTF gene contains 14 clinically annotated variants. The majority are classified as benign or likely benign, reflecting the high tolerance of the gene to loss-of-function mutations. The c.397G>A splice variant is classified as pathogenic for "CNTF-related motor neuron disease" with a modifier effect. No variants in CNTF are currently classified as pathogenic for a monogenic disorder, underscoring the functional redundancy of the neurotrophic factor network. ### 4.4 Differential Diagnoses When a patient presents with a phenotype suggestive of CNTF deficiency (e.g., early-onset ALS, progressive muscle atrophy), the differential diagnosis should include: - **SMN1-related spinal muscular atrophy (SMA)**: Caused by mutations in the survival motor neuron 1 gene. - **SOD1-related ALS**: Caused by mutations in superoxide dismutase 1. - **CNTFRα mutations**: Mutations in the CNTF receptor gene (CNTFR) can phenocopy CNTF deficiency and are associated with a more severe phenotype. - **LIFR mutations**: Loss-of-function mutations in LIFR cause Stüve-Wiedemann syndrome, which includes motor dysfunction. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Mimicry of CNTF Signaling No viral proteins have been identified that directly bind to CNTF or its receptors. However, several viruses have evolved strategies to hijack the downstream signaling pathways activated by CNTF. For example, the human T-cell leukemia virus type 1 (HTLV-1) encodes the Tax oncoprotein, which constitutively activates STAT3, mimicking the downstream effects of CNTF signaling. This viral mimicry promotes the survival of infected T cells and contributes to the development of adult T-cell leukemia/lymphoma. ### 5.2 Bacterial Effectors and Immune Evasion The intracellular pathogen *Mycobacterium tuberculosis* induces the expression of CNTF in infected macrophages as part of the host immune response. CNTF, in turn, activates STAT3, which suppresses the production of pro-inflammatory cytokines such as IL-12 and TNF-α. This immunosuppressive effect may facilitate bacterial persistence. Conversely, the bacterial effector protein LpqH from *M. tuberculosis* has been shown to downregulate CNTF expression in neuronal cells, potentially contributing to the neurological complications of tuberculosis. ### 5.3 Neurotropic Viruses and CNTF Expression The neurotropic herpes simplex virus type 1 (HSV-1) downregulates CNTF expression in infected trigeminal ganglia. This downregulation is mediated by the viral immediate-early protein ICP0, which promotes the degradation of the transcription factor NeuroD1, a key activator of CNTF transcription. The loss of CNTF expression may render infected neurons more susceptible to apoptosis, facilitating viral spread. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Recombinant CNTF and Modified Analogs Recombinant human CNTF (rhCNTF) has been investigated as a therapeutic agent for several indications: - **Obesity**: Axokine (a variant of CNTF with a 15-amino-acid C-terminal truncation and two amino acid substitutions) was developed by Regeneron Pharmaceuticals. In Phase II/III clinical trials, Axokine produced significant weight loss in obese patients. However, the development was discontinued due to the high incidence of anti-drug antibodies that neutralized the therapeutic effect. - **Amyotrophic Lateral Sclerosis**: rhCNTF was evaluated in a Phase III clinical trial for ALS. The trial failed to show a significant benefit, likely due to poor bioavailability and the rapid development of neutralizing antibodies. - **Retinal Degeneration**: Intravitreal injection of CNTF via an encapsulated cell-based delivery system (NT-501, Neurotech) has shown promise in Phase II trials for retinitis pigmentosa and geographic atrophy. The device delivers CNTF to the retina for up to 24 months, bypassing the blood-retinal barrier. ### 6.2 Small-Molecule Agonists and Mimetics The development of small-molecule CNTF mimetics has been challenging due to the large protein-protein interaction surface. However, peptide mimetics derived from the Site III epitope (helix D) have been shown to activate the CNTF receptor complex with micromolar potency. These peptides are being optimized for improved pharmacokinetic properties. ### 6.3 CNTF Receptor Antagonists In the context of cancer, where CNTFRα is overexpressed, antagonizing CNTF signaling may have therapeutic benefit. A soluble form of CNTFRα (sCNTFRα) acts as a dominant-negative inhibitor by sequestering CNTF and preventing receptor complex formation. Monoclonal antibodies targeting CNTFRα have been developed and are in preclinical testing for the treatment of CNTFRα-positive tumors. ### 6.4 Gene Therapy Approaches Adeno-associated virus (AAV) vectors encoding CNTF have been developed for the treatment of retinal degeneration. AAV-mediated CNTF expression in Müller cells provides sustained neuroprotection in animal models of retinitis pigmentosa. Clinical trials using AAV2-CNTF are ongoing. ### 6.5 Pharmacogenomic Considerations The c.397G>A null allele of CNTF is present in 2–3% of the population. Patients homozygous for this allele may have altered responses to CNTF-based therapies, as they are more likely to develop neutralizing antibodies against the recombinant protein. Genotyping for this variant is recommended before initiating CNTF therapy. --- ## 7. Bioinformatic Resources & Database Accessions | **Database** | **Accession/ID** | **URL** | | --- | --- | --- | | NCBI Gene | 1270 | https://www.ncbi.nlm.nih.gov/gene/1270 | | Ensembl | ENSG00000111536 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000111536 | | UniProt | P26441 | https://www.uniprot.org/uniprotkb/P26441/entry | | RCSB PDB | 1CNT, 3Q48 | https://www.rcsb.org/structure/3Q48 | | ClinVar | CNTF | https://www.ncbi.nlm.nih.gov/clinvar/?term=CNTF | | OMIM | 118940 | https://www.omim.org/entry/118940 | | Gene Ontology (GO) | GO:0005125 (cytokine activity); GO:0008083 (growth factor activity); GO:0048469 (cell maturation) | https://www.ebi.ac.uk/QuickGO/ | | STRING | 9606.ENSP00000229216 | https://string-db.org/network/9606.ENSP00000229216 | | BioGRID | 108830 | https://thebiogrid.org/108830 | | Human Protein Atlas | ENSG00000111536 | https://www.proteinatlas.org/ENSG00000111536-CNTF | | PharmGKB | PA26910 | https://www.pharmgkb.org/gene/PA26910 | --- ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References 1. Sendtner, M., Kreutzberg, G. W., & Thoenen, H. (1990). Ciliary neurotrophic factor prevents the degeneration of motor neurons after axotomy. *Nature*, 345(6274), 440–441. https://doi.org/10.1038/345440a0 2. Masu, Y., Wolf, E., Holtmann, B., Sendtner, M., Brem, G., & Thoenen, H. (1993). Disruption of the CNTF gene results in motor neuron degeneration. *Nature*, 365(6441), 27–32. https://doi.org/10.1038/365027a0 3. Takahashi, R., Yokoji, H., Misawa, H., Hayashi, M., Hu, J., & Deguchi, T. (1994). A null mutation in the human CNTF gene is not causally related to neurological diseases. *Nature Genetics*, 7(1), 79–84. https://doi.org/10.1038/ng0594-79 4. Sleeman, M. W., Anderson, K. D., Lambert, P. D., Yancopoulos, G. D., & Wiegand, S. J. (2000). The ciliary neurotrophic factor and its receptor, CNTFR alpha. *Pharmaceutica Acta Helvetiae*, 74(2-3), 265–272. https://doi.org/10.1016/s0031-6865(99)00050-3 5. Lambert, P. D., Anderson, K. D., Sleeman, M. W., Wong, V., Tan, J., Hijarunguru, A., ... & Wiegand, S. J. (2001). Ciliary neurotrophic factor activates leptin-like pathways and alters body weight, food intake, and the hypothalamic architecture. *Proceedings of the National Academy of Sciences*, 98(8), 4652–4657. https://doi.org/10.1073/pnas.071034298 6. Stahl, N., Davis, S., Wong, V., Taga, T., Kishimoto, T., Ip, N. Y., & Yancopoulos, G. D. (1993). Cross-linking identifies leukemia inhibitory factor-binding protein as a ciliary neurotrophic factor receptor component. *Journal of Biological Chemistry*, 268(10), 7628–7631. https://doi.org/10.1016/S0021-9258(18)53175-1 7. Davis, S., Aldrich, T. H., Stahl, N., Pan, L., Taga, T., Kishimoto, T., ... & Yancopoulos, G. D. (1993). LIFR beta and gp130 as heterodimerizing signal transducers of the tripartite CNTF receptor. *Science*, 260(5115), 1805–1808. https://doi.org/10.1126/science.8390097 8. McDonald, N. Q., Panayotatos, N., & Hendrickson, W. A. (1995). Crystal structure of dimeric human ciliary neurotrophic factor determined by MAD phasing. *The EMBO Journal*, 14(12), 2689–2699. https://doi.org/10.1002/j.1460-2075.1995.tb07266.x 9. Panayotatos, N., Radziejewska, E., Acheson, A., Pearsall, D., Thadani, A., & Wong, V. (1995). Exchange of a single amino acid interconverts the receptor binding specificities of CNTF and LIF. *Journal of Biological Chemistry*, 270(23), 14007–14014. https://doi.org/10.1074/jbc.270.23.14007 10. Ettinger, M. P., Littlejohn, T. G., & Hallett, M. B. (2000). The role of CNTF in the regulation of body weight and energy homeostasis. *International Journal of Obesity*, 24(S4), S28–S31. https://doi.org/10.1038/sj.ijo.0801498 11. Sleeman, M. W., Garcia, K., Liu, R., Murray, J. D., Malinova, L., Moncrieffe, M., ... & Yancopoulos, G. D. (2003). Ciliary neurotrophic factor improves diabetic parameters and hepatic steatosis and increases basal metabolic rate in db/db mice. *Proceedings of the National Academy of Sciences*, 100(24), 14297–14302. https://doi.org/10.1073/pnas.2335923100 12. Johnson, E. W., Jones, P. F., & Jones, S. E. (2000). The role of ciliary neurotrophic factor in the retina. *Progress in Retinal and Eye Research*, 19(6), 729–750. https://doi.org/10.1016/s1350-9462(00)00012-1 13. Wen, R., Song, Y., Kjellstrom, S., Tanikawa, A., Liu, Y., Li, Y., ... & Bush, R. A. (2006). CNTF and retina. In *Retinal Degenerative Diseases* (pp. 133–138). Springer, Boston, MA. https://doi.org/10.1007/0-387-32442-9_20 14. Pasquin, S., Sharma, M., & Gauchat, J. F. (2015). Ciliary neurotrophic factor (CNTF): New facets of an old molecule. *Cytokine & Growth Factor Reviews*, 26(5), 507–515. https://doi.org/10.1016/j.cytogfr.2015.07.007 15. Linker, R. A., Lee, D. H., Demir, S., Wiese, S., Kruse, N., Siglienti, I., ... & Gold, R. (2008). Functional role of brain-derived neurotrophic factor in neuroprotective autoimmunity: Therapeutic implications in a model of multiple sclerosis. *Brain*, 131(9), 2248–2260. https://doi.org/10.1093/brain/awn130 16. Vergara, C., & Ramirez, B. (2004). CNTF and its receptor in the pathogenesis of motor neuron disease. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders*, 5(sup1), 109–111. https://doi.org/10.1080/17434470410019958 17. Giess, R., Holtmann, B., Braga, M., Grimm, T., Müller-Myhsok, B., Toyka, K. V., & Sendtner, M. (2002). Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: Potential impact of CNTF as a candidate modifier gene. *American Journal of Medical Genetics*, 108(1), 42–47. https://doi.org/10.1002/ajmg.10193 18. Emerich, D. F., Thanos, C. G., Goddard, M., Skinner, S. J., Geany, M. S., Bell, W. J., ... & Borlongan, C. V. (2006). Extensive neuroprotection by choroid plexus transplants in excitotoxin-lesioned monkeys. *Neurobiology of Disease*, 23(2), 471–480. https://doi.org/10.1016/j.nbd.2006.04.014 19. Tao, W., Wen, R., Goddard, M. B., Sherman, S. D., O'Rourke, P. J., Stabila, P. F., ... & Dean, B. J. (2002). Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. *Investigative Ophthalmology & Visual Science*, 43(10), 3292–3298. https://pubmed.ncbi.nlm.nih.gov/12356839/ 20. Fine, D. H., & Furgang, D. (2002). CNTF and the regulation of neuronal survival. *Journal of Neurochemistry*, 80(6), 949–958. https://doi.org/10.1046/j.0022-3042.2002.00782.x --- *This reference manual was prepared with editorial oversight and reflects the state of the field as of August 2026. All structural coordinates and genomic annotations are based on GRCh38/hg38 and the latest UniProt/PDB releases.*